Status:
COMPLETED
Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma
Lead Sponsor:
Pfizer
Conditions:
Lymphoma, B-Cell
Eligibility:
All Genders
18-99 years
Phase:
PHASE1
Brief Summary
To determine the Maximum Tolerated Dose (MTD), the tolerability, and the initial safety profile of CMC-544 in subjects with B-cell Non-Hodgkin's Lymphoma (NHL).
Eligibility Criteria
Inclusion
- Subjects who have been previously diagnosed with CD22-positive, B-cell NHL, according to WHO classification, which has progressed after at least 2 prior therapies of probable clinical benefit
- At the expanded cohort, part 2 of the study, subjects must have one of the following:
- Follicular lymphoma previously treated with at least one dose of rituximab, but have not received radioimmunotherapy
- Diffuse large B-cell lymphoma
- Age 18 years or older
Exclusion
- Candidate for potentially curative therapies in the opinion of the investigator
- Chronic lymphocytic leukemia
- Burkitt's lymphoma, primary effusion lymphoma, and precursor B-cell lymphoblastic lymphoma
Key Trial Info
Start Date :
August 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
79 Patients enrolled
Trial Details
Trial ID
NCT00073749
Start Date
August 1 2003
End Date
December 1 2010
Last Update
December 17 2018
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
UAB CCC Clinical Studies Unit
Birmingham, Alabama, United States, 35233
2
University of Alabama at Birmingham Kirklin Clinic
Birmingham, Alabama, United States, 35233
3
UAB Russell Ambulatory Pharmacy
Birmingham, Alabama, United States, 35294
4
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294